抗凝固剤の世界市場レポート 2025年

抗凝固剤の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR12.7%で877億6,000万米ドルに成長します。予測期間の成長は、新規抗凝固薬の適応拡大、医療費の増加、一次治療の選択肢としての新規経口抗凝固剤（NOACs）の出現、医療施設改修のための中央当局による財政支援、医療インフラの拡大などに起因すると考えられます。予測期間における主要動向としては、医療技術や診断方法の進歩、抗凝固療法における人工知能やデータ分析の統合、患者教育やアドヒアランスプログラムの重視の高まり、逆転薬の開発などが挙げられます。

心血管疾患の罹患率の上昇は、今後数年間の抗凝固剤市場の成長を促進する重要な要因です。心血管疾患（CVDs）にはさまざまな心臓や血管の障害が含まれ、世界の死因のトップであり、中低所得国がその4分の3を占めています。抗凝固薬剤療法の一種である経口直接療法は、さまざまな心血管系疾患における血栓症を軽減するために利用されています。例えば、2024年5月、米国の政府機関である疾病対策予防センター（CDC）のデータによると、2022年の米国における心臓病による死亡者数は70万2,880人であり、そのうち37万1,506人が冠動脈疾患によるものでした。さらに、同国では毎年約80万5,000人が心臓発作に苦しんでいます。このように、心血管疾患の有病率の増加が抗凝固剤市場の拡大を促進しています。

病院数の増加が、今後の抗凝固剤市場拡大の原動力になると予測されています。病院は、さまざまな病気や怪我、病状を抱える人々に治療やケア、サポートを提供する医療施設です。抗凝固剤は、血栓の予防、血栓塞栓症の治療、心臓疾患の管理、脳卒中の再発予防、術後合併症のリスク軽減のために病院で利用されています。例えば、2024年1月、米国を拠点とする医療産業団体である米国病院協会（AHA）の報告書によると、米国では2021会計年度から2022会計年度の間に連邦政府病院が206から207に増加し、「その他」のカテゴリーの病院は107から125に増加しました。その結果、病院数の増加が抗凝固剤市場の成長に拍車をかけています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界成長分析と戦略分析フレームワーク

• 世界の抗凝固剤PESTEL分析（政治、社会、技術、環境、法的、促進要因、制約要因）
• 最終用途産業の分析
• 世界の抗凝固剤市場成長率分析
• 世界の抗凝固剤市場の実績：規模と成長、2019～2024年
• 世界の抗凝固剤市場の予測：規模と成長、2024～2029年、2034年
• 世界の抗凝固剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の抗凝固剤市場：薬剤クラス別、実績と予測、2019～2024年、2024～2029年、2034年
• 因子Xa阻害剤
• ヘパリンとLMWH
• ビタミンK拮抗薬
• その他
• 世界の抗凝固剤市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口抗凝固薬
• 注射用抗凝固剤
• 世界の抗凝固剤市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• 静脈血栓塞栓症
• 心房細動または心房粗動
• 冠動脈疾患
• その他
• 世界の抗凝固剤市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• 在宅医療
• 専門センター
• その他
• 世界の抗凝固剤市場、因子Xa阻害剤のサブセグメンテーション、タイプ別実績と予測、2019～2024年、2024～2029年、2034年
• リバロキサバン
• アピキサバン
• エドキサバン
• ベトリキサバン
• 世界の抗凝固剤市場、ヘパリンとLMWH（低分子量ヘパリン）のサブセグメンテーション、タイプ別実績と予測、2019～2024年、2024～2029年、2034年
• 未分画ヘパリン
• エノキサパリン
• ダルテパリン
• チンザパリン
• 世界の抗凝固剤市場、ビタミンK拮抗薬剤のサブセグメンテーション、タイプ別実績と予測、2019～2024年、2024～2029年、2034年
• ワルファリン
• アセノクマロール
• フェンプロクモン
• 世界の抗凝固剤市場、その他薬剤クラスのサブセグメンテーション、タイプ別実績と予測、2019～2024年、2024～2029年、2034年
• 直接トロンビン阻害剤
• 抗血小板薬
• 新規口頭発表抗凝固剤（NOAC）

第7章 地域別・国別分析

• 世界の抗凝固剤市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の抗凝固剤市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 抗凝固剤市場：競合情勢
• 抗凝固剤市場：企業プロファイル
  • GlaxoSmithKline plc
  • Leo Pharma A/S
  • Alexion Pharmaceuticals Inc.
  • Amphastar Pharmaceuticals Inc.
  • Bayer AG

第31章 その他の大手企業と革新的企業

• Boehringer Ingelheim International GmbH
• Daiichi Sankyo Company Limited
• Eisai Co. Ltd.
• Mylan N. V.
• Otsuka Holdings Co. Ltd.
• Pfizer Inc.
• Sanofi S. A.
• Apotex Inc.
• Aspen Pharmacare Holdings Limited
• AstraZeneca plc
• Bristol-Myers Squibb Company
• CSL Behring
• Dr. Reddy's Laboratories Ltd.
• Eli Lilly and Company
• Fresenius Kabi AG

第32章 世界市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 市場の最近の動向

第35章 市場の潜在力が高い国、戦略

• 抗凝固剤市場、2029年-最も新しい機会を提供する国
• 抗凝固剤市場、2029年-最も新しい機会を提供するセグメント
• 抗凝固剤市場、2029年-成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Anticoagulants, commonly known as blood thinners, are drugs used to prevent and treat blood clots in the heart and blood arteries. They work by slowing down the body's clotting process, reducing the risk of clot formation.

The main drug classes of anticoagulants include Factor Xa Inhibitor, Heparin & LMWH (Low Molecular Weight Heparin), Vitamin K Antagonist, and others. Factor Xa inhibitors specifically and reversibly block the function of clotting factor Xa, preventing clot formation. Anticoagulants can be administered orally or through injections, and they are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies. Anticoagulants are used in the treatment of conditions such as venous thromboembolism, atrial fibrillation or flutter, coronary artery disease, among others. They are employed in various healthcare settings, including hospitals, home care, specialty centers, and others.

The anticoagulants market research report is one of a series of new reports from The Business Research Company that provides anticoagulants market statistics, including anticoagulants industry global market size, regional shares, competitors with an anticoagulants market share, detailed anticoagulants market segments, market trends and opportunities, and any further data you may need to thrive in the anticoagulants industry. This anticoagulants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anticoagulants market size has grown rapidly in recent years. It will grow from $49.33 billion in 2024 to $54.39 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to aging population, increased prevalence of cardiovascular diseases, rising awareness aboutThe importance of anticoagulantTherapy, expansion of indications for anticoagulant use, increased incidence of venous thromboembolism (VTE) and atrial fibrillation.

The anticoagulants market size is expected to see rapid growth in the next few years. It will grow to $87.76 billion in 2029 at a compound annual growth rate (CAGR) of 12.7%. The growth in the forecast period can be attributed to expansion of indications for novel anticoagulant drugs, rising healthcare expenditure, emergence of novel oral anticoagulants (NOACs) as primary treatment options, financial support offered by central authorities to revamp healthcare facilities, expansion of the healthcare infrastructure. Major trends in the forecast period include advancements in medical technologies and diagnostic methods, integration of artificial intelligence and data analytics in anticoagulant therapy, growing emphasis on patient education and adherence programs, development of reversal agents.

The rising incidence of cardiovascular diseases is a significant factor propelling the growth of the anticoagulants market in the coming years. Cardiovascular diseases (CVDs) encompass a range of heart and blood vessel disorders and are the leading cause of death globally, with low- and middle-income countries accounting for three-quarters of these fatalities. Direct oral anticoagulants, a form of anticoagulation pharmacotherapy, are utilized to reduce thrombosis in various cardiovascular conditions. For example, in May 2024, data from the Centers for Disease Control and Prevention (CDC), a US-based government agency, revealed that there were 702,880 deaths from heart disease in the United States in 2022, with 371,506 of those due to coronary artery disease. Furthermore, approximately 805,000 individuals in the country suffer a heart attack each year. Thus, the growing prevalence of cardiovascular diseases is driving the expansion of the anticoagulants market.

The growing number of hospitals is anticipated to drive the expansion of the anticoagulants market in the future. Hospitals are healthcare facilities that provide medical treatment, care, and support to individuals dealing with various illnesses, injuries, or medical conditions. Anticoagulants are utilized in hospitals to prevent blood clots, treat thromboembolic disorders, manage heart conditions, prevent recurrent strokes, and reduce the risk of postoperative complications. For example, in January 2024, a report from the American Hospital Association (AHA), a US-based healthcare trade organization, indicated that in the United States, federal government hospitals increased from 206 to 207 between fiscal years 2021 and 2022, while hospitals in the "other" category grew from 107 to 125. Consequently, the rising number of hospitals is fueling the growth of the anticoagulants market.

Major companies in the anticoagulants market are concentrating on developing innovative solutions, such as factor Xa inhibitor tests, to address the rising demand for testing stemming from the increased use of direct oral anticoagulants for stroke prevention and other severe cardiovascular conditions. Factor Xa Inhibitor Tests are designed to assess the effectiveness and safety of anticoagulant medications that selectively inhibit factor Xa, thereby preventing blood clot formation in various medical scenarios. For example, in February 2024, F. Hoffmann-La Roche Ltd., a Switzerland-based biotechnology company, introduced coagulation tests for apixaban, edoxaban, and rivaroxaban. These new coagulation tests for Factor Xa inhibitors employ Roche's innovative reagent cassette concept, which ensures high-quality results and efficient sample processing while providing standardization and automation for improved laboratory workflows. These tests are crucial as they aid clinical decision-making for patients using direct oral anticoagulants for stroke prevention, catering to the growing global demand for effective diagnostics in managing serious conditions like coronary artery disease and peripheral arterial disease.

Prominent entities within the anticoagulants market are directing their focus towards innovative products, such as the sodium citrate 4% anticoagulant solution, to bolster their market revenues. This medical solution consists of a liquid form containing 4% sodium citrate, serving the purpose of preventing blood clotting. For instance, in August 2023, Fresenius Kabi AG, a Germany-based healthcare group specializing in pharmaceuticals and medical devices, introduced the sodium citrate 4% anticoagulant solution. When utilized in conjunction with apheresis equipment, this solution becomes vital for collecting and preserving blood and its components. The 250 mL container of sodium citrate 4% anticoagulant solution is meticulously crafted to adhere to Canada's stringent requirements for plasma donation. By binding calcium ions, sodium citrate effectively prevents the coagulation cascade, maintaining blood in a liquid state suitable for diagnostic testing and various medical procedures.

In August 2022, Pharmaniaga Berhad, a Malaysia-based pharmaceutical company, forged a partnership with Suzhou Ronnsi Pharma Co. Ltd. This strategic collaboration aims to address the escalating demand for therapies targeting non-communicable diseases, driven by an aging population, and specifically caters to the burgeoning market for halal medications. The partnership between Pharmaniaga Berhad and Suzhou Ronnsi Pharma Co. Ltd aims to facilitate commerce in pharmaceutical products, research and development initiatives, and ultimately, the production of a halal ovine anticoagulant product. Suzhou Ronnsi Pharma Co. Ltd, based in China, specializes in manufacturing anticoagulants and forms a crucial part of this collaboration aimed at meeting the growing demand for halal pharmaceuticals in the market.

Major companies operating in the anticoagulants market include GlaxoSmithKline plc, Leo Pharma A/S, Alexion Pharmaceuticals Inc., Amphastar Pharmaceuticals Inc., Bayer AG, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Mylan N. V., Otsuka Holdings Co. Ltd., Pfizer Inc., Sanofi S. A., Apotex Inc., Aspen Pharmacare Holdings Limited, AstraZeneca plc, Bristol-Myers Squibb Company, CSL Behring, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Fresenius Kabi AG, Hikma Pharmaceuticals plc, Johnson & Johnson, Lupin Limited, Mitsubishi Tanabe Pharma Corporation, Natco Pharma Limited, Novartis International AG, Portola Pharmaceuticals Inc., Strides Pharma Science Limited, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Limited, Torrent Pharmaceuticals Limited, Zydus Cadila Healthcare Limited

North America was the largest region in the anticoagulants market in 2024. The regions covered in the anticoagulants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the anticoagulants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The anticoagulants market consists of sales of rivaroxaban, dabigatran, apixaban, and edoxaban. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Anticoagulants Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anticoagulants market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for anticoagulants ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The anticoagulants market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Factor Xa Inhibitor; Heparin And LMWH; Vitamin K Antagonist; Other Drug Classes
• 2) By Route Of Administration: Oral Anticoagulant; Injectable Anticoagulant
• 3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• 4) By Application: Venous Thromboembolism; Atrial Fibrillation Or Flutter; Coronary Artery Disease; Other Applications
• 5) By End User: Hospitals; Homecare; Specialty Centers; Other End-Users
• Subsegments:
• 1) By Factor Xa Inhibitor: Rivaroxaban; Apixaban; Edoxaban; Betrixaban
• 2) By Heparin And LMWH (Low Molecular Weight Heparin): Unfractionated Heparin; Enoxaparin; Dalteparin; Tinzaparin
• 3) By Vitamin K Antagonist: Warfarin; Acenocoumarol; Phenprocoumon
• 4) By Other Drug Classes: Direct Thrombin Inhibitors; Antiplatelet Agents; Novel Oral Anticoagulants (NOACs)
• Companies Mentioned: GlaxoSmithKline plc; Leo Pharma A/S; Alexion Pharmaceuticals Inc.; Amphastar Pharmaceuticals Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Anticoagulants Market Characteristics

3. Anticoagulants Market Trends And Strategies

4. Anticoagulants Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Anticoagulants Growth Analysis And Strategic Analysis Framework

• 5.1. Global Anticoagulants PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Anticoagulants Market Growth Rate Analysis
• 5.4. Global Anticoagulants Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Anticoagulants Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Anticoagulants Total Addressable Market (TAM)

6. Anticoagulants Market Segmentation

• 6.1. Global Anticoagulants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Factor Xa Inhibitor
• Heparin And LMWH
• Vitamin K Antagonist
• Other Drug Classes
• 6.2. Global Anticoagulants Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Anticoagulant
• Injectable Anticoagulant
• 6.3. Global Anticoagulants Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Venous Thromboembolism
• Atrial Fibrillation Or Flutter
• Coronary Artery Disease
• Other Applications
• 6.4. Global Anticoagulants Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Centers
• Other End-Users
• 6.5. Global Anticoagulants Market, Sub-Segmentation Of Factor Xa Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rivaroxaban
• Apixaban
• Edoxaban
• Betrixaban
• 6.6. Global Anticoagulants Market, Sub-Segmentation Of Heparin And LMWH (Low Molecular Weight Heparin), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Unfractionated Heparin
• Enoxaparin
• Dalteparin
• Tinzaparin
• 6.7. Global Anticoagulants Market, Sub-Segmentation Of Vitamin K Antagonist, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Warfarin
• Acenocoumarol
• Phenprocoumon
• 6.8. Global Anticoagulants Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Direct Thrombin Inhibitors
• Antiplatelet Agents
• Novel Oral Anticoagulants (NOACs)

7. Anticoagulants Market Regional And Country Analysis

• 7.1. Global Anticoagulants Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Anticoagulants Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Anticoagulants Market

• 8.1. Asia-Pacific Anticoagulants Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Anticoagulants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Anticoagulants Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Anticoagulants Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Anticoagulants Market

• 9.1. China Anticoagulants Market Overview
• 9.2. China Anticoagulants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Anticoagulants Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Anticoagulants Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Anticoagulants Market

• 10.1. India Anticoagulants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Anticoagulants Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Anticoagulants Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Anticoagulants Market

• 11.1. Japan Anticoagulants Market Overview
• 11.2. Japan Anticoagulants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Anticoagulants Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Anticoagulants Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Anticoagulants Market

• 12.1. Australia Anticoagulants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Anticoagulants Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Anticoagulants Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Anticoagulants Market

• 13.1. Indonesia Anticoagulants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Anticoagulants Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Anticoagulants Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Anticoagulants Market

• 14.1. South Korea Anticoagulants Market Overview
• 14.2. South Korea Anticoagulants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Anticoagulants Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Anticoagulants Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Anticoagulants Market

• 15.1. Western Europe Anticoagulants Market Overview
• 15.2. Western Europe Anticoagulants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Anticoagulants Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Anticoagulants Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Anticoagulants Market

• 16.1. UK Anticoagulants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Anticoagulants Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Anticoagulants Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Anticoagulants Market

• 17.1. Germany Anticoagulants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Anticoagulants Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Anticoagulants Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Anticoagulants Market

• 18.1. France Anticoagulants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Anticoagulants Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Anticoagulants Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Anticoagulants Market

• 19.1. Italy Anticoagulants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Anticoagulants Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Anticoagulants Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Anticoagulants Market

• 20.1. Spain Anticoagulants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Anticoagulants Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Anticoagulants Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Anticoagulants Market

• 21.1. Eastern Europe Anticoagulants Market Overview
• 21.2. Eastern Europe Anticoagulants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Anticoagulants Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Anticoagulants Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Anticoagulants Market

• 22.1. Russia Anticoagulants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Anticoagulants Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Anticoagulants Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Anticoagulants Market

• 23.1. North America Anticoagulants Market Overview
• 23.2. North America Anticoagulants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Anticoagulants Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Anticoagulants Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Anticoagulants Market

• 24.1. USA Anticoagulants Market Overview
• 24.2. USA Anticoagulants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Anticoagulants Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Anticoagulants Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Anticoagulants Market

• 25.1. Canada Anticoagulants Market Overview
• 25.2. Canada Anticoagulants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Anticoagulants Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Anticoagulants Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Anticoagulants Market

• 26.1. South America Anticoagulants Market Overview
• 26.2. South America Anticoagulants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Anticoagulants Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Anticoagulants Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Anticoagulants Market

• 27.1. Brazil Anticoagulants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Anticoagulants Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Anticoagulants Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Anticoagulants Market

• 28.1. Middle East Anticoagulants Market Overview
• 28.2. Middle East Anticoagulants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Anticoagulants Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Anticoagulants Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Anticoagulants Market

• 29.1. Africa Anticoagulants Market Overview
• 29.2. Africa Anticoagulants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Anticoagulants Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Anticoagulants Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Anticoagulants Market Competitive Landscape And Company Profiles

• 30.1. Anticoagulants Market Competitive Landscape
• 30.2. Anticoagulants Market Company Profiles
  • 30.2.1. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Leo Pharma A/S Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Alexion Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Amphastar Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Anticoagulants Market Other Major And Innovative Companies

• 31.1. Boehringer Ingelheim International GmbH
• 31.2. Daiichi Sankyo Company Limited
• 31.3. Eisai Co. Ltd.
• 31.4. Mylan N. V.
• 31.5. Otsuka Holdings Co. Ltd.
• 31.6. Pfizer Inc.
• 31.7. Sanofi S. A.
• 31.8. Apotex Inc.
• 31.9. Aspen Pharmacare Holdings Limited
• 31.10. AstraZeneca plc
• 31.11. Bristol-Myers Squibb Company
• 31.12. CSL Behring
• 31.13. Dr. Reddy's Laboratories Ltd.
• 31.14. Eli Lilly and Company
• 31.15. Fresenius Kabi AG

32. Global Anticoagulants Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Anticoagulants Market

34. Recent Developments In The Anticoagulants Market

35. Anticoagulants Market High Potential Countries, Segments and Strategies

• 35.1 Anticoagulants Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Anticoagulants Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Anticoagulants Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer